2026– date –
-
2026 LLM Leaderboard Reveals Llama 4 Scout as Fastest at 2600 Tokens/Sec, GPT-5.3 Codex Achieves Lowest Latency at 0.003s
Vellum USA Overview The updated 2026 LLM leaderboard, incorporating data from April 2024 onwards, showcases Llama 4 Scout as the fastest model at 2600 tokens/second, while GPT-5.3 Codex records the lowest latency at 0.003 seconds. Nova M... -
Multimodal Foundation Model SQUALL Integrates Histology with Spatial Molecular Programs, Revolutionizing Cancer Biomarker Profiling and Outcome Prediction
bioRxiv International Overview Researchers have developed SQUALL, a multimodal foundation model that integrates histology with spatial molecular programs to deepen the mechanistic interpretation of histopathological assessments. Pretrain... -
Claude Opus 4.8 Achieves Peak Accuracy of 89.08% in Financial LLM Benchmark, Gemini 3.5 Flash Also Highly Rated
AIMultiple USA Overview In a benchmark evaluating over 40 Large Language Models (LLMs) on complex financial reasoning tasks, Anthropic's Claude Opus 4.8 attained the highest accuracy at 89.08%. Google's Gemini 3.5 Flash also demonstrated... -
Tempus AI Unveils Promising Initial Results from Oncology Multimodal Foundation Model Trained on 2.5M Longitudinal Records, Achieving C-index of 0.802 for OS Prediction
Business Wire USA Overview Tempus AI announced initial results at ASCO 2026 for its multimodal foundation model aimed at oncology insight generation. This transformer-based model, trained on 2.5 million longitudinal records, 450,000 digi... -
A Quarter of Enterprise AI Agent Deployments Fail ROI Targets, Citing Governance and IAM Deficiencies
ITSM.tools 他 UK Overview New 2026 research indicates that 25% of AI agent deployments in large UK enterprises are failing to achieve their expected ROI, primarily due to critical governance gaps. Key challenges include the absence of pu... -
FDA-Cleared AI “Artera AI Breast” Demonstrates Clinical Utility for Breast Cancer Prognosis and Chemotherapy Benefit Prediction at ASCO 2026
The Pathologist USA Overview At ASCO 2026, a study showcased the utility of Artera AI Breast, an FDA-cleared multimodal artificial intelligence model, for predicting prognosis and chemotherapy benefit in postmenopausal women with node-po... -
OpenAI, Anthropic, Microsoft CEOs Call for Stricter Laws Against AI Biothreats to Synthetic DNA/RNA
Financial Express USA Overview CEOs from OpenAI, Anthropic, and Microsoft AI, alongside over 50 other signatories, have pressed the US Congress to implement more stringent regulations on synthetic DNA and RNA to mitigate AI-enabled bioth... -
AI/ML Transforms Drug Discovery, Boosting Efficiency and Precision from Target to Clinic
PubMed Central (Preprints経由) International Overview A recent review underscores the transformative impact of AI and Machine Learning (AI/ML) across the entire drug discovery pipeline, from initial target identification to clinical tria... -
ImmunoFoundation: Novel Multimodal Foundation Model for Immunogenicity Prediction and Peptide Optimization Overcomes Data Scarcity
OpenReview USA Overview Researchers have introduced ImmunoFoundation, a self-supervised multimodal foundation model designed for immunogenicity prediction and peptide optimization. By integrating an ESM-2 sequence encoder with a graph tr... -
Energy & Storage Strategy Weekly Report — Vol. 48 (2026.05.25 — 05.31)
Vol. 48 | 2026.05.25 — 05.31 | Market Mood: 70 / 100 — Cautiously Optimistic The energy transition accelerates, with Asian firms like CATL and Chinese institutions leading commercialization in advanced battery (500 Wh...
